GSKPHARMA Q2 : CONS NET PROFIT UP 30.4% AT ₹335.88 CR (YOY), UP 41.6% (QOQ). STRONG (ON 1ST LOOK)

Revenue up 20.8% at ₹1183.57 Cr (YOY), up 26.1% (QOQ). Ebitda up 28.6% at ₹474.85 Cr (YOY), up 40.0% (QOQ); margins 40.1% v 37.7% (YOY), 36.2% (QOQ). Caution: other income includes ₹42.09 Cr interest on income tax refund.

GlaxoSmithKline Pharmaceuticals Ltd

Open attachment

← Back to feed